- Home
- FDMM vs EDIT Comparison
FDMM vs EDIT Comparison
Compare FDMM & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FDMM | EDIT |
|---|---|---|
| Founded | 2026 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 369.3M | 422.3M |
| IPO Year | 2026 | 2016 |
Fundamental Metrics
Financial Performance| Metric | FDMM | EDIT |
|---|---|---|
| Price | $9.83 | $2.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $6.10 |
| AVG Volume (30 Days) | 59.1K | ★ 2.1M |
| Earning Date | N/A | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $9.80 | $1.66 |
| 52 Week High | $9.88 | $3.94 |
Technical Indicators
Market Signals| Indicator | FDMM | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 52.67 | 37.80 |
| Support Level | $9.80 | $1.82 |
| Resistance Level | $9.84 | $2.29 |
| Average True Range (ATR) | 0.01 | 0.24 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 75.00 | 13.08 |
Price Performance
Historical ComparisonAbout FDMM Freedom Metals Acquisition Corp. Class A Ordinary Shares
Freedom Metals Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.